SAR study of tyrosine-chlorambucil hybrid regioisomers; Synthesis and biological evaluation against breast cancer cell lines

Amino Acids

Volumn 43, Issue 2, 2012, Pages 923-935

  Descôteaux, Caroline ^a   Brasseur, Kevin ^a   Leblanc, Valerie ^a   Parent, Sophie ^a   Asselin, Éric ^a   Bérubé, Gervais ^a  

^a UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

Author keywords

Breast cancer; Metatyrosine chlorambucil hybrid; Ortho tyrosine chlorambucil hybrid; Para tyrosine chlorambucil hybrid; Tyrosine chlorambucil hybrid

Indexed keywords

CHLORAMBUCIL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; META TYROSINE CHLORAMBUCIL; ORTHO TYROSINE CHLORAMBUCIL; PARA TYROSINE CHLORAMBUCIL; PHENOL; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; IN VITRO STUDY; METHODOLOGY; MOLECULAR DOCKING; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHLORAMBUCIL; COMPUTER SIMULATION; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; HYDROGEN BONDING; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE;

EID: 84864777428     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-011-1152-3     Document Type: Article

References (27)

1. Armitage JO (1993) LeukeranR (Chlorambucil). In: Borroughs Wellcome Co (ed) Current Clinical Guide, 2nd edn. Oncology Products Wellcome Oncology NMC Publ. Inc, New York, p 37
2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28(1):235-242
3. Bertin C, Weston LA, Huang T, Jander G, Owens T, Meinwald J, Schroeder FC (2007) Grass roots chemistry: meta-Tyrosine, an herbicidal nonprotein amino acid. Proc Natl Acad Sci 104(43):16964
4. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47(4):936-942
5. Chrzanowski K, Bielawska A, Palka J (2003) Proline analogue of melphalan as a prodrug susceptible to the action of prolidase in breast cancer MDA-MB 231 cells. Farmaco 58(11):1113-1119
6. Contino-Pépin C, Parat A, Périno S, Lenoir C, Vidal M, Galons H, Karlik S, Pucci B (2009) Preliminary biological evaluations of new thalidomide analogues for multiple sclerosis application. Bioorganic Med Chem Lett 19(3):878-881
7. Demyttenaere-Kovatcheva A, Cronin MTD, Benfenati E, Roncaglioni A, LoPiparo E (2005) Identification of the structural requirements of the receptor-binding affinity of diphenolic azoles to estrogen receptors a and b by three-dimensional quantitative structure-activity relationship and structure-activity relationship analysis. J Med Chem 48(24):7628-7636
8. Descoteaux C, Leblanc V, Brasseur K, Gupta A, Asselin E, Berube G (2010) Synthesis of D-and L-tyrosine-chlorambucil analogs active against breast cancer cell lines. Bioorganic Med Chem Lett 20(24):7388-7392. doi:10.1016/j.bmcl.2010. 10.039
9. Durand G, Prosak RA, Han Y, Ortial S, Rockenbauer A, Pucci B, Villamena FA (2009) Spin trapping and cytoprotective properties of fluorinated amphiphilic carrier conjugates of cyclic versus linear nitrones. Chem Res Toxicol 22(9):1570-1581
10. Gabano E, Cassino C, Bonetti S, Prandi C, Colangelo D, Ghiglia A, Osella D (2005) Synthesis and characterisation of estrogenic carriers for cytotoxic Pt(II) fragments: biological activity of the resulting complexes. Org Biomol Chem 3(19):3531-3539. doi: 10.1039/b507716h
11. Gengrinnovitch S, Izakovich E (2005) Conjugates of amino acids with drugs or with imaging agents for cancer therapy and diagnosis Israel Patent, WO 2005072061
12. Gupta A, Saha P, Descoteaux C, Leblanc V, Asselin E, Berube G (2010) Design, synthesis and biological evaluation of estradiol-chlorambucil hybrids as anticancer agents. Bioorganic Med Chem Lett 20(5):1614-1618. doi:10.1016/j.bmcl.2010.01.053
13. Gust R, Beck W, Jaouen G, Schönenberger H (2009) Optimization of cisplatin for the treatment of hormone dependent tumoral diseases: Part 1: use of steroidal ligands. Coord Chem Rev 253(21-22):2742-2759. doi:10.1016/j.ccr. 2009.02.025
14. Joy S, Nair PS, Hariharan R, Pillai MR (2006) Detailed comparison of the protein-ligand docking efficiencies of GOLD, a commercial package and ArgusLab, a licensable freeware. In Silico Biol 6(6):601-605
15. Karl J, Gust R, Spruss T, Schneider MR, Schoenenberger H, Engel J, Wrobel KH, Lux F, Haeberlin ST (1988) Ring-substituted [1, 2-bis (4-hydroxyphenyl) ethylenediamine] dichloroplatinum (II) complexes: compounds with a selective effect on the hormonedependent mammary carcinoma. J Med Chem 31(1):72-83
16. Magrath IT (1994) Targeted approaches to cancer therapy. Int J Cancer 56(2):163-166
17. Muthyala RS, Carlson KE, Katzenellenbogen JA (2003) Exploration of the bicyclo[3.3.1]nonane system as a template for the development of new ligands for the estrogen receptor. Bioorganic Med Chem Lett 13(24):4485-4488
18. Ortial S, Durand G, Poeggeler B, Polidori A, Pappolla MA, Böker J, Hardeland R, Pucci B (2006) Fluorinated amphiphilic amino acid derivatives as antioxidant carriers: a new class of protective agents. J Med Chem 49(9):2812-2820
19. Otto AM, Faderl M, Schönenberger H (1991) Dissociation of estrogenic and cytotoxic properties of an estrogen receptorbinding platinum complex in human breast cancer cell lines. Cancer Res 51(12):3217
20. Palmer AJ, Wallace HM (2010) The polyamine transport system as a target for anticancer drug development. Amino acids 38(2):415-422
21. Perrin D, Armarego W (1988) Purification of laboratory chemicals. Pergamon Press edn, Oxford
22. Sachdeva MS (1998) Drug targeting systems for cancer chemotherapy. Expert Opin Investig Drugs 7(11):1849-1864. doi: 10.1517/13543784.7.11.1849
23. Shanle EK, Xu W (2010) Selectively targeting estrogen receptors for cancer treatment. Adv Drug Deliv Rev 62(13):1265-1276. doi: 10.1016/j.addr.2010. 08.001
24. Still W, Kahn M, Mitra A (1978) Rapid chromatographic techniques for preparative separation with moderate resolution. J Org Chem 43(14):2923
25. Tanenbaum DM, Wang Y, Williams SP, Sigler PB (1998) Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci USA 95(11):5998-6003
26. Thompson MA (2004) Molecular docking using ArgusLab, an efficient shape-based search algorithm and the AScore scoring function. In: ACS meeting, Philadelphia Thompson MA ArgusLab 4.0. Seattle
27. Van Themsche C, Parent S, Leblanc V, Descoteaux C, Simard AM, Berube G, Asselin E (2009) VP-128, a novel oestradiolplatinum( II) hybrid with selective anti-tumour activity towards hormone-dependent breast cancer cells in vivo. Endocr Relat Cancer 16(4):1185-1195. doi:10.1677/ERC-09-0113